According to the World Health Organization (WHO) “globally, more than 2.2 billion people are affected by vision impairment, with at least half of them having an eye condition that could have been prevented or is yet to be addressed”
Mirtogenol®, a patented combination of Pycnogenol® French maritime pine bark extract and Mirtoselect® bilberry extract, is one of the first nutritional approaches developed to address eye health. The supplement addresses aspects related to the challenges associated with the increase in intraocular pressure, a major contributor to eye-related health risks. Common eye conditions like cataracts, uncorrected refractive errors, and glaucoma, if untreated, can lead to blindness.
Mirtogenol® has been studied in various clinical trials, demonstrating significant effects on intraocular pressure (IOP) and ocular blood flow (OBF). It positively impacts eye health by strengthening retinal capillaries, reducing the recurrence of retinal vein thrombosis, and providing potent antioxidant protection. Clinical studies with Mirtogenol® show a substantial reduction in IOP, improvement in ocular blood flow velocity, and potential preventive benefits for symptomatic glaucoma. Other studies indicate enhanced effects when combined with traditional antihypertensive drugs, maintaining retinal nerve fiber layer thickness, and improving visual fields.
The patented combination offers a safe, natural, and evidence-based solution for supporting eye health.
For more information, visit www.mirtogenol.com.
